


# Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

## Graphical abstract



## Highlights

- Simplified direct-acting antiviral treatment monitoring produced high efficacy and tolerability.
- Direct-acting antiviral adherence was high and equivalent with simplified and standard monitoring.
- Further research evaluating simplified monitoring of direct-acting antiviral treatment is warranted.

## Authors

Gregory J. Dore, Jordan J. Feld, Alex Thompson, ..., Fernando Tatsch, Ana Gabriela Pires Dos Santos, Ed Gane

## Correspondence

gdore@kirby.unsw.edu.au  
(G.J. Dore)

## Lay summary

Direct-acting antiviral (DAA) therapy for hepatitis C is highly effective and well tolerated. The SMART-C randomised trial evaluated an 8-week regimen of glecaprevir-pibrentasvir for hepatitis C treatment, using a simplified monitoring schedule that included no pathology tests or clinic visits during treatment. This simplified strategy produced a high cure rate (92%), but this was not equivalent to the standard monitoring schedule cure rate (95%).



# Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

Gregory J. Dore<sup>1,2,\*</sup>, Jordan J. Feld<sup>3</sup>, Alex Thompson<sup>4,5</sup>, Marianne Martinello<sup>1</sup>, Andrew J. Muir<sup>6</sup>, Kosh Agarwal<sup>7</sup>, Beat Müllhaupt<sup>8</sup>, Heiner Wedemeyer<sup>9</sup>, Karine Lacombe<sup>10</sup>, Gail V. Matthews<sup>1,2</sup>, Michael Schultz<sup>11</sup>, Marina Klein<sup>12</sup>, Christophe Hezode<sup>13</sup>, Gerard Estivill Mercade<sup>1</sup>, Danny Kho<sup>1</sup>, Kathy Petoumenos<sup>1</sup>, Philippa Marks<sup>1</sup>, Fernando Tatsch<sup>14</sup>, Ana Gabriela Pires Dos Santos<sup>14</sup>, Ed Gane<sup>15</sup>, on behalf of the SMART-C Study Group

<sup>1</sup>Kirby Institute, UNSW Sydney, Sydney, Australia; <sup>2</sup>St Vincent's Hospital, Sydney, Australia; <sup>3</sup>Toronto Centre for Liver Disease, Toronto General Hospital, Toronto, Canada; <sup>4</sup>St Vincent's Hospital, Melbourne, Australia; <sup>5</sup>University of Melbourne, Melbourne, Australia; <sup>6</sup>Duke University School of Medicine, Durham, United States; <sup>7</sup>Institute of Liver Studies, King's College Hospital, London, United Kingdom; <sup>8</sup>University Hospital, Zürich, Switzerland; <sup>9</sup>University Clinic Essen, Essen, Germany; <sup>10</sup>Sorbonne Université, IPLESP, Saint-Antoine Hospital, AP-HP, Paris, France; <sup>11</sup>Dunedin Hospital, Dunedin, New Zealand; <sup>12</sup>McGill University Health Centre, Montreal, Canada; <sup>13</sup>University of Paris-Est, INSERM U955, Henri Mondor Hospital, AP-HP, Creteil, France; <sup>14</sup>Abbvie Inc., North Chicago, IL, United States; <sup>15</sup>Auckland Hospital, Auckland, New Zealand

**Background & Aims:** Direct-acting antiviral (DAA) therapy for HCV has high efficacy and limited toxicity. We hypothesised that the efficacy of glecaprevir-pibrentasvir for chronic HCV with a simplified treatment monitoring schedule would be non-inferior to a standard treatment monitoring schedule.

**Methods:** In this open-label multicentre phase IIIb trial, treatment-naïve adults with chronic HCV without cirrhosis were randomly assigned (2:1) to receive glecaprevir-pibrentasvir 300 mg–120 mg daily for 8 weeks administered with a simplified or standard monitoring strategy. Clinic visits occurred at baseline and post-treatment week 12 in the simplified arm, and at baseline, week 4, week 8, and post-treatment week 12 in the standard arm. Study nurse phone contact occurred at week 4 and week 8 in both arms. Participants requiring adherence support were not eligible, including those reporting recent injecting drug use. The primary endpoint was sustained virological response at post-treatment week 12 (SVR12), with a non-inferiority margin of 6%.

**Results:** Overall, 380 participants (60% male, 47% genotype 1, 32% genotype 3) with chronic HCV were randomised and treated with glecaprevir-pibrentasvir in the simplified (n = 253) and standard (n = 127) arms. In the intention-to-treat population, SVR12 was 92% (95% CI 89%–95%) in the simplified and 95% (95% CI 92%–99%) in the standard arm (difference between arms –3.2%; 95% CI –8.2% to 1.8%) and did not reach non-inferiority. In the per-protocol population, SVR12 was 97% (95% CI 96%–99%) in the simplified and 98% (95% CI 96%–100%) in the standard arm. No treatment-related serious adverse events were reported.

**Conclusions:** In patients with chronic HCV infection without cirrhosis, treatment with glecaprevir-pibrentasvir was safe and effective. In comparison to standard monitoring, a simplified monitoring schedule did not achieve non-inferiority.

Trial Registration: clinicaltrials.gov Identifier: NCT03117569.

**Lay summary:** Direct-acting antiviral (DAA) therapy for hepatitis C is highly effective and well tolerated. The SMART-C randomised trial evaluated an 8-week regimen of glecaprevir-pibrentasvir for hepatitis C treatment, using a simplified monitoring schedule that included no pathology tests or clinic visits during treatment. This simplified strategy produced a high cure rate (92%), but this was not equivalent to the standard monitoring schedule cure rate (95%).

© 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

## Introduction

Globally, an estimated 71 million people have chronic HCV infection.<sup>1</sup> HCV treatment was interferon-based for more than 2 decades, with the addition of ribavirin,<sup>2</sup> pegylated-interferon,<sup>3</sup> and first-generation protease inhibitor direct-acting antiviral (DAA) therapies (telaprevir, boceprevir),<sup>4,5</sup> providing stepwise improvements in efficacy as defined by sustained virological response (SVR). Despite these improvements, treatment uptake remained low in most countries, with <1% to 5% of people with chronic HCV initiating therapy each year.<sup>6</sup>

Recent years have seen a revolution in HCV therapeutic development, with the availability of interferon-free DAA regimens.<sup>7</sup> Simple (once daily dosing oral regimens), well tolerated, short duration (8–12 weeks), pangenotypic DAA therapy with high efficacy (cure rates above 95%) is now standard of care for chronic HCV. The broad implementation of DAA therapy has considerable public health potential, with the World Health Organization setting ambitious HCV elimination impact targets for reductions in HCV incidence (80%) and liver disease mortality (65%) by 2030.<sup>8</sup>

Keywords: Hepatitis C; Treatment; Direct-acting antivirals; Simplified monitoring.  
Received 11 June 2019; received in revised form 2 September 2019; accepted 15 October 2019; available online 23 October 2019

\* Corresponding author. Address: The Kirby Institute, UNSW Sydney, Wallace Wurth Building, UNSW NSW 2052 Australia.

E-mail address: [gdore@kirby.unsw.edu.au](mailto:gdore@kirby.unsw.edu.au) (G.J. Dore).



The capacity to scale-up DAA therapy should be enhanced by simplified treatment monitoring strategies. The coformulation of glecaprevir-pibrentasvir, an NS3/4a protease inhibitor and NS5A inhibitor combination, provides key features for HCV treatment simplification, including on-treatment monitoring: i) pan-genotypic activity with high efficacy; ii) minimal drug-related toxicity; iii) ease of dosing (3 pills once daily); and iv) short duration (8 weeks for patients without cirrhosis). In phase III clinical trials in patients without cirrhosis, an 8-week regimen of glecaprevir-pibrentasvir (300 mg–120 mg) led to SVR rates of 95–100% in HCV genotypes 1–6.<sup>9,10</sup>

We hypothesised that a simplified monitoring schedule would be non-inferior to a standard monitoring strategy in terms of SVR at post-treatment week 12 (SVR12), in treatment-naïve patients with chronic HCV (genotypes 1–6).

### Patients and methods

#### Study design and randomisation

In this open-label international multicentre phase IIIb trial, treatment-naïve adults with chronic HCV and without cirrhosis were randomly assigned (2:1) to receive glecaprevir-pibrentasvir 300 mg–120 mg for 8 weeks administered with a simplified or standard monitoring strategy (SMART-C; Fig. 1). Randomisation was computer-generated and stratified according to HCV genotype (genotype 1 or non-genotype 1) and country. The treatment assignments were not concealed. Glecaprevir-pibrentasvir was administered orally once daily as 3 fixed-dose combination tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir, for a total daily dose of 300 mg of glecaprevir and 120 mg of pibrentasvir.

#### Participants


From 21 August 2017 to 16 July 2018, participants were screened and enrolled at 33 sites in Australia (n = 6), Canada (n = 7), France (n = 3), Germany (n = 4), New Zealand (n = 4),

Switzerland (n = 2), the United Kingdom (n = 3), and the United States (n = 4). Study recruitment was conducted through a network of tertiary specialist viral hepatitis clinics (n = 30), and primary care clinics (n = 3). Scheduled study follow-up continued through 14 December 2018, when the final participant enrolled was assessed for SVR12.

Participants who were at least 18 years of age were eligible for participation if they had chronic HCV genotypes 1–6, were HCV treatment-naïve (interferon-based or DAA) and did not have cirrhosis. The absence of cirrhosis in all participants was assessed by means of transient elastography or aspartate aminotransferase-to-platelet ratio index (APRI). The absence of cirrhosis was defined as a liver stiffness measurement by transient hepatic elastography of <12.5 kPa or APRI of <1.0. Individuals receiving opiate agonist therapy and those with HIV coinfection were eligible. Participants who were considered by their clinician to require additional treatment adherence support were not eligible, although a standardised adherence assessment tool was not used across sites. The suitability for enrolment in relation to perceived adherence support needs was based on clinical judgement and was at the discretion of the site investigator, reflecting clinical practice and enhancing generalisability. Participants who self-reported injecting drug use within the previous 6 months or those who tested positive on urinary drug screen at screening were not eligible. Individuals with acute or chronic HBV coinfection (HBsAg positive) were excluded. Participants with prior HBV infection (HBsAg negative, antibody to HBcAg positive) were eligible. Full eligibility criteria are provided in the study protocol, available with the full text of this article in the supplementary files.

#### Study assessments

In the standard arm, scheduled clinic study visits were undertaken at baseline, treatment weeks 4 and 8 (end of treatment), and post-treatment week 12. In the simplified arm, scheduled clinic study visits were undertaken at baseline and post-



**Fig. 1. Study design.** Treatment-naïve adults with chronic HCV and without cirrhosis were randomly assigned (2:1) to receive glecaprevir-pibrentasvir 300 mg–120 mg for 8 weeks administered with a simplified or standard monitoring strategy. In the standard arm, scheduled face-to-face clinic study visits were undertaken at baseline, treatment weeks 4 and 8 (end of treatment), and post-treatment week 12. In the simplified arm, scheduled face-to-face clinic study visits were undertaken at baseline and post-treatment week 12. In both the standard and simplified arms, phone contact was initiated by the study nurse at weeks 4 and 8 (end of treatment). Study drug dispensing occurred at baseline and week 4 in the standard arm, and at baseline only in the simplified arm. GLE-PIB, glecaprevir-pibrentasvir; SVR12, sustained virological response at post-treatment week 12.

treatment week 12. Assessments at these visits included measurement of vital signs, symptom-directed physical examinations, assessment of HCV RNA, and standard laboratory testing. In the standard arm, study drug was dispensed at baseline and treatment week 4. In the simplified arm, study drug was fully dispensed at baseline. To standardise reporting and data collection, in both the standard and simplified arms, phone contact was initiated by the study nurse at weeks 4 and 8 (end of treatment) to monitor treatment adherence and adverse events using a structured case report form and questionnaire. For participants in the standard arm, phone contact was initiated 1 to 2 days prior to their planned clinic visit at weeks 4 and 8. All adverse events were recorded and graded according to a standard scale (see study protocol for details). Study drug adherence was assessed by self-reported adherence questionnaires at weeks 4 and 8 (phone contact), and pill count at week 8 (standard arm) or post-treatment week 12 (simplified arm). Participants were asked to return study drug packaging (and any unused medication) at end of treatment (standard arm) or post-treatment week 12 (simplified arm), with the number of pills returned recorded by the site coordinator and pharmacist.

The presence of HCV RNA in plasma was assessed at all scheduled clinic study visits using Aptima HCV Quant Dx assay, version 2.15.5 (lower limit of quantification [LLOQ] 10 IU/ml; Hologic, Inc., Marlborough, MA, USA), with centralised testing performed at St Vincent's Centre for Applied Medical Research (Sydney, NSW, Australia). Reverse transcription of RNA with random hexamers was performed using the Invitrogen Superscript™ system (Vilo IV), and the Core-E2, NS5A and NS3 HCV regions were amplified by PCR.<sup>11,12</sup> Sanger sequencing was performed at the Australian Genome Research Facility on the Applied Biosystems™ 3730xl DNA Analyzer. Sequence curation was performed using RECall.<sup>13</sup> The presence of polymorphisms in NS3 and NS5A at baseline was evaluated using Geno2PhenoHCV. Among participants with virological failure, substitutions (relative to an individual's baseline HCV sequence) that developed on-treatment were examined.

### Study definitions

Stage of liver fibrosis was assessed by liver stiffness measurement (transient elastography [FibroScan®]) or APRI. For liver stiffness measurements, the chosen cut-offs for significant liver fibrosis and cirrhosis were 7.1 kPa and 12.5 kPa, respectively.<sup>14</sup> APRI below 1.0 excluded cirrhosis with high specificity.<sup>15</sup>

HCV virological suppression was defined as HCV RNA below the LLOQ. An end of treatment response was defined as HCV RNA below the LLOQ (target not detected or target detected, not quantifiable) at the end of treatment (date of treatment cessation).

HCV treatment outcome was classified as SVR12 (defined as HCV RNA below the LLOQ at or after 12 weeks post cessation of treatment), virologic failure (HCV RNA above the LLOQ at 12 weeks post cessation of treatment with reinfection excluded on sequencing) or non-virologic failure (including reinfection, death, premature treatment discontinuation, loss to follow-up or missing HCV RNA values). In the standard monitoring arm, HCV virologic failure was further defined as on-treatment failure (non-response or breakthrough) or post-treatment relapse (presence of quantifiable HCV RNA after end of treatment with detection of infection with an HCV strain consistent with the primary infecting strain, confirmed as homologous virus on sequencing). Reinfection was defined as HCV RNA above the

LLOQ after end of treatment with detection of infection with an HCV strain that was distinct from the primary infecting strain, confirmed as heterologous virus on sequencing.

### Study endpoints

The primary endpoint was SVR12 by intention-to-treat following glecaprevir-pibrentasvir for 8 weeks, administered with a standard or simplified monitoring schedule, in patients with chronic HCV who were treatment naïve and did not have cirrhosis. Secondary endpoints included premature treatment discontinuation, treatment adherence, and treatment-emergent serious adverse events.

### Statistical analysis and sample size

A total of 375 participants (2:1 randomisation) were planned for enrolment and evaluation as the intention-to-treat population. With these participant numbers and under the assumption that the proportion achieving SVR12 would be 96% in both arms, the study had approximately 80% power to show non-inferiority of the simplified monitoring strategy compared to the standard monitoring strategy, with a lower confidence bound for SVR12 in the simplified monitoring arm greater than 90% or with a lower confidence bound for the difference (simplified arm minus standard arm) in SVR12 greater than -6%. The 90% threshold for non-inferiority in the standard monitoring arm was based on the clinical trial data available at the time of study design (SVR12 96%), minus a 6% non-inferiority margin.<sup>9,16</sup> The non-inferiority margin of 6% was selected in accordance with the principles outlined in guidance on conducting non-inferiority trials;<sup>17,18</sup> the choice of margin ensured minimal to no loss of efficacy.

Primary efficacy and safety data were analysed in the intention-to-treat population (all enrolled participants for efficacy and safety, as all received study drug), with loss to follow-up deemed treatment failure. The modified intention-to-treat population included participants in the intention-to-treat population, but excluded those who did not attend follow-up at or after post-treatment week 12. The per-protocol population included participants who completed the prescribed 8-week treatment course and attended follow-up after treatment. SVR12 assessment was nominally set at post-treatment day 84, with a lower limit of post-treatment day 70. The upper limit was not specified and was set to study close.

Categorical parameters were summarised as number and proportion. Continuous variables were summarised as either mean (SD) or median (IQR), as appropriate. For all efficacy endpoints, means and proportions with 2-sided 95% CIs were determined. Adherence was measured by a self-reported adherence questionnaire (on-treatment week 4 and 8) at phone contact visits, and by pill count at post-treatment week 12. On-treatment adherence was calculated by subtracting the number of missed doses from the total number of doses prescribed for therapy duration and dividing by the total number of doses prescribed for therapy duration. By pill count and self-reported questionnaire, glecaprevir-pibrentasvir adherence was individually calculated at the 90/90 and 95/95 levels, defined as receipt of ≥90% or ≥95% of scheduled doses for ≥90% or ≥95% of the scheduled treatment period, respectively. In calculating adherence, pill count took precedence over self-report if discrepancies were noted. A participant was considered adherent if that individual received ≥95% of scheduled doses for ≥95% of the scheduled treatment period. Analysis was performed using STATA (version 15.0; StataCorp, College Station, TX).

**Study oversight**

All participants provided written informed consent before study procedures. The study protocol was approved by St. Vincent’s Hospital, Sydney Human Research Ethics Committee (primary study committee), as well as through local ethics committees at all study sites, and was conducted according to the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice (ICH/GCP) guidelines. The study was registered with clinicaltrials.gov (NCT03117569).

**Role of the funding source**

The study (including study medications) was funded by a research grant from AbbVie. The sponsor (The Kirby Institute, UNSW Sydney) collected the data, managed study samples, monitored study conduct, performed the statistical analysis, and drafted the manuscript.

**Results**

Of 433 participants screened between 21 August 2017 to 16 July 2018, 380 were enrolled and randomised into the simplified (n = 253) and standard (n = 127) arms (Fig. 2). Of the 53 participants excluded at screening, 43 (81%) did not meet eligibility criteria, most commonly due to HCV RNA <10,000 IU/ml (n = 18), and positive urinary drug screen (n = 10) (Table S2).


The demographic and clinical characteristics of enrolled participants were similar between the arms (Table 1). Overall, median age was 51 years, and 39% were female. The genotype distribution included 47% (n = 179) genotype 1 (1a 33%, n = 124; 1b 13%, n = 51; 1 no subtype 1%, n = 4); 14% (n = 52) genotype 2; 32% (n = 121) genotype 3; 5% (n = 18) genotype

4; <1% (n = 1) genotype 5; 2% (n = 8) genotype 6. One participant had an indeterminate genotype. Median baseline HCV RNA was 6.3 log<sub>10</sub> IU/ml (IQR 5.4–7.0), with baseline HCV RNA >1,000,000 IU/ml (>6 log<sub>10</sub>) in 59% (n = 101) and >10,000,000 IU/ml (>7 log<sub>10</sub>) in 22% (n = 83). HIV coinfection was documented in 7% (n = 27), with median CD4 count 698 cells x 10<sup>6</sup>/L and HIV viral load below 50 copies/ml in 89% (n = 24; 3 participants had missing results at screening). All participants with HIV were receiving antiretroviral therapy (n = 27) (Table S5).

Among all participants enrolled, the prevalence of polymorphisms in NS3 and NS5A was 19% and 16%, respectively, and was seen with similar frequency in the simplified and standard arms (Table S6). The most common NS5A polymorphisms were at positions 28 and 30. The prevalence of the Y93H/N variant was 3% in the simplified arm and 3% in the standard arm (Table S6). Among participants with HCV genotype 3, the prevalence of the A30K variant was 2% (5/253) in the simplified arm and 1% (1/127) in the standard arm.

Among all participants enrolled, 99% (simplified arm 98%; standard arm 100%) completed their treatment course. Of the 4 participants in the simplified arm who did not complete treatment, 2 discontinued treatment (both within week 1), 1 due to an adverse event and 1 unwilling to continue, and 2 were lost to follow-up on-treatment (Table 2). Overall, 96% of participants were ≥95% adherent to the prescribed treatment course (simplified arm 95%; standard arm 98%; difference between arms -3.2%, 95% CI -6.6%–0.2%) (Table 2).

In the intention-to-treat population (n = 380), SVR12 was 92% (233/253; 95% CI 88%–95%) in the simplified arm and 95% (121/127; 95% CI 90%–98%) in the standard arm (difference



**Fig. 2. Participant disposition.** The number of participants screened (n = 433), randomised (n = 380) and analysed (intention-to-treat population/full analysis set, n = 380) is depicted. Of the 53 participants who were excluded, 43 did not meet the inclusion criteria, 5 were lost to follow-up, and 5 withdrew consent. Reasons for failing the inclusion criteria included i) chronic HCV infection (n = 1), ii) HCV RNA plasma ≥ 10,000 IU/ml (n = 18) and iii) fibrosis stage F0–F3 (n = 6). Reasons for failing the exclusion criteria included i) history of significant comorbid illness or decompensated liver disease (n = 1), ii) abnormal laboratory parameters (n = 5), iii) receipt of anti-neoplastic or immunomodulatory therapy within 6 months (n = 1), iv) positive urine drug screen (n = 10) and v) injecting drug use within 6 months (n = 1).

**Table 1. Baseline demographic, clinical and virological characteristics in the intention-to-treat population.**

	<b>Total study population, n = 380</b>	<b>Standard monitoring arm, n = 127</b>	<b>Simplified monitoring arm, n = 253</b>
Age, median (range)	51 (22–79)	50 (24–79)	52 (22–73)
Gender, n (%)			
Male	229 (60)	72 (57)	157 (62)
Female	149 (39)	53 (42)	96 (38)
Transgender	2 (1)	2 (2)	0
Ethnicity, n (%)			
White	291 (77)	97 (76)	194 (77)
Asian	34 (9)	12 (9)	22 (9)
Black	20 (5)	7 (6)	13 (5)
Other	35 (9)	11 (9)	24 (9)
BMI, median (range)	25.0 (17.8–51.5)	24.7 (18.2–51.5)	25.3 (17.8–41.7)
HCV genotype, n (%)			
Genotype 1	179 (47)	61 (48)	118 (47)
1a	124	47	77
1b	51	14	37
1 not specified	4	0	4
Genotype 2	52 (14)	17 (13)	35 (14)
Genotype 3	121 (32)	41 (32)	80 (32)
Genotype 4	18 (5)	4 (3)	14 (6)
Genotype 5	1 (<1)	1 (1)	0
Genotype 6	8 (2)	3 (2)	5 (2)
Genotype indeterminate	1 (<1)	0	1 (<1)
HCV RNA			
Log <sub>10</sub> , median (range)	6.28 (2.49–7.74)	6.29 (2.85–7.71)	6.27 (2.49–7.74)
Fibrosis stage, n (%) <sup>a</sup>			
No or mild fibrosis (F0/F1)	283 (74)	93 (73)	190 (75)
Moderate fibrosis (F2)	78 (21)	29 (23)	49 (19)
Severe fibrosis (F3)	19 (5)	5 (4)	14 (6)
HIV infection, n (%)	27 (7)	13 (10)	14 (6)
CD4 count (10 <sup>6</sup> /L), median (range)	698 (372–984)	652 (372–984)	698 (446–863)
HIV viral load ≤50 at screening, n (%)	24 (89)	12 (92)	12 (86)
On antiretroviral therapy, n (%)	27 (100)	13 (100)	14 (100)
Opioid substitution therapy, n (%)	38 (10)	17 (13)	21 (8)

APRI, aminotransferase-to-platelet ratio index; LSM, liver stiffness measurement.

<sup>a</sup> Categorisation of fibrosis stage: No or mild fibrosis (F0/F1): LSM < 7.1 kPa or APRI < 0.5; significant fibrosis (F2): LSM 7.1–9.4 kPa or APRI 0.5–1.0; severe fibrosis (F3): LSM 9.5–12.4 kPa.

between arms –3.2%, 95% CI –8.2% to 1.8%) (Table 3, Fig. 3). Thus, non-inferiority of the simplified arm to the standard arm was not shown, with the 95% lower confidence bound for the difference in SVR12 rates falling below –6% (–8.2%).

In the modified intention-to-treat population (n = 364), which excluded participants who died (n = 1), were lost to follow-up (n = 14), or had missing HCV RNA results (n = 1; unable to perform phlebotomy due to difficult venous access), SVR12 was 97% (233/241; 95% CI 94%–99%) in the simplified arm and 98% (121/123; 95% CI 94%–100%) in the standard arm (difference between arms –1.7%; 95% CI –4.9% to 1.5%) (Table 3).

In the per-protocol population (n = 362), excluding participants who died (n = 1), discontinued treatment (n = 2), were lost to follow-up (n = 14) or had missing HCV RNA results (n = 1), SVR12 was 97% (233/239; 95% CI 95%–99%) in the simplified arm and 98% (121/123; 95% CI 94%–100%) in the standard arm (difference between arms –0.9%; 95% CI –3.9% to 2.1%) (Table 3).

The proportion with SVR12 (including 95% CI) stratified by key characteristics is shown in the supplementary information (Table S8A,B). In the intention-to-treat population, SVR12 was higher among participants with genotype 1 (96%) compared to those with non-genotype 1 infection (91%; p = 0.03; Fig. 3); SVR was 91% among participants with genotype 3. In the per-protocol population, SVR12 was similar among participants with genotype 1 (99%) compared to those with non-genotype

1 infection (97%; p = 0.12); SVR12 was 97% among participants with genotype 3. In the intention-to-treat population, SVR12 was higher among participants who were ≥95% adherent to therapy (345/366, 94%) compared to those <95% adherent to therapy (9/14, 64%; p <0.001). Of the 5 non-adherent participants without an SVR12, 2 were early treatment discontinuations and 3 were lost to follow-up.

Overall, 26 participants did not achieve SVR12 (simplified arm, 20/253; standard arm, 6/127; Table 3), with the majority related to loss to follow-up. There were 8 cases of virological failure, including 6 (2.4%) in the simplified arm and 2 (1.6%) in the standard arm (Table 3). All participants with virological failure were ≥95% adherent to treatment. Further details on participants with virologic failure are provided (Table S9A,B).

There were 14 participants lost to follow-up, 4 (3%) in the standard arm and 10 (4%) in the simplified arm. No baseline factors were significantly associated with loss to follow-up, although the rate was higher among those aged less than 50 years (6%) compared to older participants (2%) (Table S10). Of note, among study participants lost to follow-up (n = 14) or without SVR12 assessment (n = 1), adherence reporting was available in 13 participants and was reported as above 95% in all.

Of the 380 participants enrolled, 1 participant (<1%) discontinued treatment prematurely because of an adverse event (simplified arm 1/253; standard arm 0/127) (Table 4). Overall, 53% of participants experienced at least 1 adverse event (simpli-

**Table 2. Treatment completion, adherence and visit attendance in the intention-to-treat population.**

	Total study population, n = 380	Standard monitoring arm, n = 127	Simplified monitoring arm, n = 253
<b>Treatment completion, n (%)</b>			
Commenced treatment	380 (100)	127 (100)	253 (100)
Completed allocated treatment course	376 (99)	127 (100)	249 (98)
Discontinued treatment, n (%)	2 (<1)	0	2 (1)
Adverse event <sup>1</sup>	1	0	1
Non-compliance <sup>2</sup>	1	0	1
Lost to follow-up on treatment, n (%) <sup>3</sup>	2 (<1)	0	2 (1)
<b>Visit attendance</b>			
Week 4, n (%)			
Phone contact	352 (93)	113 (89)	239 (94)
Clinic visit	n.a.	127 (100)	n.a.
Week 8, n (%)			
Phone contact	348 (92)	114 (90)	234 (92)
Clinic visit	n.a.	124 (98)	
<b>Adherence</b>			
Overall adherence, n (%)			
≥95%	366 (96)	125 (98)	241 (95)
≥90%	370 (97)	126 (99)	244 (96)
Missed doses, by treatment period <sup>4</sup>			
Week 0–4			
Any missed doses, n (%)	28 (5)	3 (3)	25 (10)
Number of missed doses, median (range) <sup>5</sup>	1 (1–5)	1 (1–1)	1 (1–5)
Week 5–8			
Any missed doses, n (%)	41 (12)	13 (11)	28 (12)
Number of missed doses, median (range)	1 (1–13)	1 (1–3)	1 (1–13)

n.a., not applicable.

<sup>1</sup> Participant discontinued treatment after day 5 due to an adverse event (gastrointestinal disorder, mild).

<sup>2</sup> Participant discontinued treated after day 2, reason for discontinuation unclear.

<sup>3</sup> Including 1 participant who was incarcerated while on-treatment.

<sup>4</sup> Assessed by self-report during phone contact at week 4 (n = 352) and week 8 (n = 348).

<sup>5</sup> Median number of missed doses among those reporting 1 or more missed doses.


**Table 3. Treatment outcomes, primary and secondary efficacy endpoints.**

Outcome	Standard monitoring arm, n (%)	Simplified monitoring arm, n (%)	Difference between arms (95% CI)
<b>Intention to treat population</b>			
	<b>n = 127</b>	<b>n = 253</b>	
SVR12, n (%)	121 (95)	233 (92)	-3.2% (-8.2% to 1.8%)
Virologic failure, n (%)	2 (2)	6 (2)	0.8% (-2.1% to 3.7%)
On-treatment failure	0	n.a.	
Post-treatment relapse	2	n.a.	
Failure for other reasons, n (%)	4 (3)	14 (6)	-2.2% (-6.3% to 2.0%)
Death	0	1 (<1)	
Discontinuation	0	2 (1)	
Lost to follow-up or missing HCV RNA <sup>1</sup>	4 (3)	11 (4)	
<b>Modified intention to treat population</b>			
	<b>n = 123</b>	<b>n = 241</b>	
SVR12, n (%)	121 (98)	233 (96)	-1.7% (-4.9% to 1.5%)
Virologic failure, n (%)	2 (2)	6 (2)	
On-treatment failure	0	n.a.	
Post-treatment relapse	2	n.a.	
Failure for other reasons, n (%)	0	2 (1%)	
<b>Per-protocol population</b>			
	<b>n = 123</b>	<b>n = 239</b>	
SVR12, n (%)	121 (98)	233 (97)	-0.9% (-3.9% to 2.1%)
Virologic failure, n (%)	2 (2)	6 (2)	
On-treatment failure	0	n.a.	
Post-treatment relapse	2	n.a.	

<sup>1</sup> Missing HCV RNA: 1 participant in the simplified arm completed study follow-up and attended clinical review at post-treatment week 12, but given difficult venous access, phlebotomy was unsuccessful. SVR12, sustained virological response at post-treatment week 12.

fied arm 133/253; standard arm 70/127), of which the majority were of mild to moderate severity (Table 4). The most common adverse events were fatigue, headache and nausea, with similar rates in the simplified and standard arms (Table 4). Three participants (simplified arm 3/253; standard arm 0/127) experienced a treatment-emergent serious adverse event; none was deemed related to treatment (Table S12). One participant died after post-treatment week 4 due to lung adenocarcinoma.

Adverse event reporting was similar across arms, despite the additional clinic-based contact in the standard arm. Among all treatment-emergent adverse events reported in the simplified arm (n = 294), most were reported by phone at week 4 (64%, n = 188) or week 8 (20%, n = 60). Among all treatment-emergent adverse events reported in the standard arm (n = 192), most were reported by phone at week 4 (59%, n = 114) or week 8 (17%, n = 33); a minority were reported at



**Fig. 3. Efficacy in the intention-to-treat and per-protocol population.** Dotted line at 90% representing the lower bound of the 95% CI for the standard (control) arm. SVR, sustained virological failure.

scheduled clinic visits at week 4 (13%, n = 25) or week 8 (5%, n = 9).

Participants underwent unscheduled reviews during the study (in addition to protocol mandated clinic visits or phone contact) with similar frequency in the simplified arm (8%; 20/253) and the standard arm (6%; 8/127) ( $p = 0.68$ ), of which only a small number presented for additional review on-treatment (simplified arm 4%, 11/253; standard arm 2%, 3/127; Table S15).

## Discussion

Among treatment-naïve patients with chronic HCV infection without cirrhosis, the efficacy of glecaprevir-pibrentasvir for 8 weeks with a simplified treatment monitoring schedule did not achieve non-inferiority compared to a standard treatment monitoring schedule. In the intention-to-treat population, the

SVR was 92% in the simplified arm and 95% in the standard arm. The lower SVR in the simplified arm did not relate to virological failure (simplified arm 2.4%; standard arm 1.6%). A higher proportion with non-virological failure in the simplified arm (5.5%) compared with the standard arm (3.1%) contributed to the difference in efficacy, including early treatment discontinuations in 2 participants, 1 death, and a marginally higher loss to follow-up (4.3% vs. 3.1%). Safety was comparable across both arms. These findings suggest that for many patients, particularly those without cirrhosis or adherence concerns, a simplified treatment monitoring schedule may be appropriate. Equally, the findings highlight the need for careful selection of patients for simplified treatment monitoring and the need to optimise post-treatment follow-up.

A per-protocol SVR of 97%–98% across the study arms is consistent with the high efficacy of 8-week glecaprevir-pibrentasvir demonstrated in phase III clinical trials (95%–99%).<sup>9</sup> The lower intention-to-treat SVR in SMART-C (92%–95%) is attributed to a higher loss to follow-up, with recruitment into this investigator-initiated trial through a large network of tertiary and primary care sites. The majority of those lost to follow-up after treatment (n = 14) had reported high adherence during treatment, and thus may have been cured. There were no baseline factors associated with loss to follow-up, although the power to detect such associations was limited by the small sub-population.

A lack of non-inferiority in SVR between simplified and standard arms was observed, with a difference in efficacy of –3.2% (95% CI –8.2%–1.8%). The study sample was determined, based on an expected SVR of 96% and a non-inferiority margin of 6%. This primary endpoint difference in intention-to-treat efficacy may reflect a true decrement in treatment outcome due to the simplified monitoring approach, or alternatively be a limitation of the study power (sample size provided 80% power to determine non-inferiority).

A simplified on-treatment monitoring schedule, with nurse phone contact at week 4 and week 8 (end of treatment) and no face-to-face clinic visits or laboratory assessments, was safe

**Table 4. Safety parameters, adverse events, and treatment discontinuation in the intention-to-treat population.**<sup>^</sup>

Adverse events	Standard monitoring arm, n = 127	Simplified monitoring arm, n = 253
Participants reporting any TEAE up to 30 days after last dose, n (%)	70 (55)	133 (53)
Grades 1–2	69 (54)	131 (52)
Grade 3	1 (1)	2 (1)
Grade 4	0	0
Participants reporting TEAE up to 30 days after last dose, n (%)	50 (39)	86 (34)
Grades 1–2	50 (39)	85 (34)
Grade 3	0	1 (<1)
Grade 4	0	0
Serious TEAE, n (%)	0	3 (1)*
Treatment-related serious TEAE, n (%)	0	0
Treatment discontinuation due to adverse event, n (%)	0	1 (<1)
Death, n (%)	0	1 (<1) <sup>‡</sup>
Adverse events		
Common (>5% of study population), n (%)		
Fatigue	30 (14)	52 (15)
Headache	26 (12)	43 (13)
Nausea	25 (12)	17 (5)
Unscheduled clinic visits or phone contact		
Any timepoint following enrolment, n (%)	8 (6)	20 (8)
On treatment, n (%)	3 (2)	11 (4)

TEAE, treatment-emergent adverse event.

<sup>^</sup>The intention-to-treat population (full analysis set) and the safety population were the same.

\* These events were deemed by the investigators as having no reasonable possibility of being related to the trial drugs. Additional information on serious adverse events is provided in the supplementary information.

<sup>‡</sup> The participant died after post-treatment week 4 from lung adenocarcinoma (unrelated to the study drug or study conduct).

and associated with high treatment adherence. Adverse event and adherence reporting were standardised across the randomised arms, with all study participants reporting via study nurse phone calls at week 4 and 8. Based on this reporting, adverse events were comparable across the study arms, in terms of overall adverse event occurrence (simplified arm 53%; standard arm 55%), pattern of adverse events, and serious adverse events (simplified arm 1%; standard arm 0%).

Adherence to glecaprevir-pibrentasvir (taken as 3 co-formulated pills once daily) was high in both arms ( $\geq 95\%$  adherent to prescribed treatment course; simplified arm 95%; standard arm 98%). The absence of a week 4 clinical visit and virological assessment in the simplified arm had limited impact on treatment adherence. The proportion of participants missing at least 1 dose by week 4 was higher in the simplified (10%) compared to standard (3%) arm, although this measure was similar by week 8 (12% vs. 11%). Furthermore, the SVR in those missing at least 1 dose by week 4 in the simplified arm was high (100%), consistent with most of these participants missing only 1 dose. The potency and predictability of DAA therapy means the vast majority of patients have either undetectable or very low-level HCV RNA at week 4. Early virological assessment has therefore been considered more important for monitoring of treatment adherence.

The eligibility criteria for SMART-C highlight the need for careful clinical assessment, including discussion of adherence support needs, prior to recommending a simplified monitoring schedule. For example, people who reported injecting drug use within 6 months of screening were not eligible for enrolment due to their generally enhanced support needs. We have undertaken clinical trials of DAA therapy among people who inject drugs, that have demonstrated high adherence and efficacy, but these trials have incorporated weekly clinic visits during treatment.<sup>19</sup> Adherence rates decline with increasing treatment complexity, longer duration of therapy, and more than daily dosing,<sup>20–25</sup> highlighting the importance of simple HCV treatment strategies to optimise adherence and outcomes.

Some HCV treatment guidelines have already incorporated optional on-treatment virological monitoring. The European Association for the Study of the Liver (EASL) recommends that among patients receiving DAA therapy, HCV RNA (or HCV core antigen) and alanine aminotransferase should be measured at baseline and at post-treatment week 12 (or 24) to assess treatment efficacy (level of evidence: A1) and safety (level of evidence: B1), respectively.<sup>26</sup> Indeed, the current EASL recommendations push the boundary further and suggest that “given the high SVR12 rates expected with these regimens across all groups of patients if adherent, checking SVR12 12 weeks after the end of treatment is dispensable (level of evidence: B1/B2)”.<sup>26</sup> The American Association for the Study of the Liver guidelines remain more conservative, recommending on-treatment laboratory assessments of efficacy (HCV RNA) and safety (liver and renal function; level of evidence: B1).<sup>27</sup>

The lack of non-inferiority in the SMART-C study indicates that caution should be exercised in relation to the EASL guidelines regarding simplified on-treatment monitoring. The possibility remains that some patients, even within the restricted eligibility of the SMART-C study, may have benefited from standard on-treatment monitoring. We also believe that documentation of SVR12 remains an important component of HCV therapeutic management, despite a low virological failure rate. The SMART-C study incorporated a nurse phone contact at week

4 and 8 (end of treatment). This contact may have assisted treatment adherence and post-treatment follow-up, therefore our findings should not be extrapolated to situations without this form of patient contact.

The SMART-C study has some limitations that should be considered. First, although the protocol excluded patients whom the clinician judged to have treatment adherence concerns, a standardised adherence assessment tool was not incorporated within the study. Second, the study population was restricted to patients who were HCV treatment naïve, without cirrhosis, and recruited in high-income countries, largely through tertiary clinics. Further studies of simplified monitoring are required in different settings and populations. Importantly, the MINMON (clinicaltrials.gov; NCT03512210) single-arm trial is evaluating a simplified monitoring schedule for sofosbuvir-velpatasvir in the United States and several low- and middle-income countries. Finally, a cost-effectiveness evaluation has not been undertaken to date. Clinical care cost reductions through a simplified monitoring schedule could be offset if the SVR is reduced, even by a small margin.

Additional aspects of simplified monitoring that could be evaluated, are the need for phone contact on-treatment, and mechanisms to enhance post-treatment follow-up, including self-collection and posting of samples (such as dried blood spots) for SVR12 assessment. A key aspect of simplified monitoring trials is provision of the full course of therapy at treatment initiation, 8 weeks therapy with glecaprevir-pibrentasvir for SMART-C and 12 weeks therapy with sofosbuvir-velpatasvir for MINMON. Incorporation of this simplified aspect may require regulatory changes in relation to pharmacy dispensing in different countries.

In conclusion, the SMART-C study has demonstrated high adherence, high tolerability, and high treatment efficacy with an 8-week regimen of glecaprevir-pibrentasvir in patients with chronic HCV who are treatment naïve and without cirrhosis. Although the comparison of simplified to standard treatment monitoring did not achieve non-inferiority, we believe that simplified monitoring can be recommended for many patients with chronic HCV, following careful individualised clinical assessment, including adherence support needs. Progress towards achieving the WHO HCV elimination 2030 goals should be enhanced through greater simplification of DAA treatment and monitoring.

### Abbreviations

APRI, aminotransferase-to-platelet ratio index; DAA, direct-acting antiviral; EASL, European Association for the Study of the Liver; GLE-PIB, glecaprevir-pibrentasvir; LLoQ, lower limit of quantification; LSM, liver stiffness measurement; SVR, sustained virological response; SVR12, SVR at post-treatment week 12; TEAE, treatment-emergent adverse event.

### Financial support

This study was an investigator-initiated trial primarily funded by AbbVie.

### Conflict of interest

The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. Research reported in this publication

was supported by AbbVie. FT and AS are employees of AbbVie, Inc., and may hold stock or stock options. None of the other authors has commercial relationships that might pose a conflict of interest in connection with this manuscript.

Please refer to the accompanying [ICMJE disclosure](#) forms for further details.

### Authors' contributions

GJD designed and proposed the study, with study design contributions from JJF, AT, EG, PM, FT, and AGPDS. GJD, JJF, AT, AJM, KA, BM, HW, KL, GVM, MS, MK, CH, and EG were involved in participant recruitment and data collection. GJD, MM, GVH, GEM, DK, KP, and PM were involved in study coordination. GJD, JJF, AT, AJM, KA, BM, HW, KL, KP, PM, and EG provided study governance through the Protocol Steering Committee. MM conducted the data analyses, with oversight from KP and GJD. GJD and MM drafted the manuscript, with input from all authors. All authors have seen and approved the final version of the manuscript.

### Acknowledgements

The SMART-C study group includes members of the Protocol Steering Committee; Coordinating Centre, The Kirby Institute, UNSW Sydney; and Study Site Principal Investigators.

**Protocol Steering Committee** – Gregory Dore (Chair, The Kirby Institute, UNSW Sydney, Sydney, Australia), Ed Gane (Auckland City Hospital, Auckland, New Zealand), Jordan Feld (Toronto General Hospital, Toronto, Canada), Alexander Thompson (St Vincent's Hospital Melbourne, Melbourne, Australia), Pip Marks (The Kirby Institute, UNSW Sydney, Sydney, Australia), Andrew Muir (Duke University Medical Center, Durham, United States), Kosh Agarwal (King's College Hospital, London, United Kingdom), Beat Müllhaupt (University of Zurich, Zürich, Switzerland), Heiner Wedemeyer (University Clinic Essen, Essen, Germany), Karine Lacombe (Saint-Antoine Hospital, Paris, France), Ana Pires Dos Santos (AbbVie, Chicago, United States) and Roger Trinh (AbbVie, Chicago, United States).

**Coordinating Centre, The Kirby Institute, UNSW Sydney, Sydney, Australia** – Amanda Erratt (Study co-ordinator), Gerard Estivill Mercade (Study co-ordinator), Danny Kho (Study co-ordinator), Sophie Quiene (Study Co-ordinator), Gregory Dore (Co-ordinating principal investigator), Pip Marks (Clinical Trials Manager), Ineke Shaw (Systems Manager), Ecaterina Filep (Data Manager), Marianne Martinello (Research Fellow, Statistician) and Kathy Petoumenos (Statistician).

**Site Principal Investigators** – Stuart Roberts (The Alfred Hospital, Melbourne, Australia), Ed Gane (Auckland City Hospital, Auckland, New Zealand), Graham Foster (Barts Health, London, United Kingdom), Michael Curry (Beth Israel Deaconess Medical Center, Boston, United States), Jenny Warlow (Calder Center, Auckland, New Zealand), Stefan Mauss (Center for HIV and Hepatogastroenterology, Dusseldorf, Germany), Catherine Stedman (Christchurch Hospital, Christchurch, New Zealand), Marie-Louise Vachon (Chu de Québec Université Laval, Quebec, Canada), Stefan Christensen (CIM Infectious Diseases, Muenster, Germany), Andrew Muir (Duke University Medical Center, Durham, United States), Michael Schultz (Dunedin Hospital, Dunedin, New Zealand), David Baker (East Sydney Doctors, Sydney, Australia), Alnoor Ramji (G.I.R.I, Vancouver, Canada), Markus Cornberg (Hannover Medical School, Hannover, Germany), Mark Bloch (Holdsworth House Medical Practice, Sydney, Australia),

Christophe Hézode (Hôpital Henri Mondor, Université Paris-Est Créteil, France), Marc Bourlière (Hôpital Saint-Joseph, Marseille, France), Karine Lacombe (Hopital St Antoine, Paris, France), Nasser Semmo (Inselspital Bern, Bern, Switzerland), Kosh Agarwal and Mary Cannon (Kings College, London, United Kingdom), Edward Tam (LAIR Centre, Vancouver, Canada), Marina Klein (McGill University Health Centre, Montreal, Canada), Ira Jacobson (New York University Langone Medical Center, New York, United States), David Shaw (Royal Adelaide Hospital, Adelaide, Australia), James Levin (SSM Dean Medical Group, Madison, United States), Keith Tsoi (St Josephs Hospital, Hamilton, Canada), Graham Cooke (St Mary's Hospital, London, United Kingdom), Alexander Thompson (St Vincent's Hospital Melbourne, Melbourne, Australia), Gail Matthews (St Vincent's Hospital Sydney, Sydney, Australia), Jordan Feld (Toronto General Hospital, Toronto, Canada), Sergio M Borgia (William Osler Health System, Toronto, Canada), Axel Baumgarten (ZIBP, Berlin, Germany) and Beat Müllhaupt (University Hospital Zürich, Zürich, Switzerland).

The authors would like to thank the study participants for their contribution to the research. The authors would also like to acknowledge the work undertaken by the Study Site Coordinators.

**Site Co-ordinators and Site Co-investigators** – Jo Mitchell (The Alfred Hospital, Melbourne, Australia), Christine Crooks (Auckland City Hospital, Auckland, New Zealand), James Hand and Christopher Sivell (Barts Health, London, United Kingdom), Sheila Wilson (Beth Israel Deaconess Medical Center, Boston, United States), Victoria Oliver (Calder Center, Auckland, New Zealand), Andreas Kamp (Center for HIV and Hepatogastroenterology, Dusseldorf, Germany), Tracy Noonan (Christchurch Hospital, Christchurch, New Zealand), Fanie Bourgault and Isabelle Chabot (Chu de Québec Université Laval, Quebec, Canada), Sabine Offermann (CIM Infectious Diseases, Muenster, Germany), Tina Lucas (Duke University Medical Center, Durham, United States), Merrilee Williams (Dunedin Hospital, Dunedin, New Zealand), Melissa Benson, Britt Johnson and Roshanak Mousavi (East Sydney Doctors, Sydney, Australia), Maria Anchetaschmit (G.I.R.I, Vancouver, Canada), Linda Hinneburg (Hannover Medical School, Hannover, Germany), Beatrice Lecomte (Hôpital Henri Mondor, Université Paris-Est Creteil, France), Ben Gallagher and Annabelle Casperz (Holdsworth House Medical Practice, Sydney, Australia), Laurence Lecomte and Christine Hernandez (Hôpital Saint-Joseph, Marseille, France), Kathrin Husi and Dunja Heck (Inselspital Bern, Bern, Switzerland), Andrew Ayers and Jeya Sundararaj (Kings College, London, United Kingdom), Diane Lambie and Taryn Tyrrell (LAIR, Vancouver, Canada), Lina Del Balso (McGill University Health Centre, Montreal, Canada), Mary Olson (New York University Langone Medical Center, New York, United States), Catherine Ferguson (Royal Adelaide Hospital, Adelaide, Australia), Brenda Gehin (SSM Dean Medical Group, Madison, United States), Dr Jessica Krause and Christian Tran (Hopital St Antoine, Paris, France), Barbara Baker (St Joseph's Hospital, Hamilton, Canada), Dr Christopher Jones, Michael Wood and Ajerico Del Rosario (St Mary's Hospital, London, United Kingdom), Nicole Tresize (St Vincent's Hospital Melbourne, Melbourne, Australia), Alison Sevehan (St Vincent's Hospital Sydney, Sydney, Australia), Orlando Cerrochi (Toronto General Hospital, Toronto, Canada), Sharon Bojarski (William Osler Hospital, Toronto, Canada), Jan Gumprecht (ZIBP, Berlin, Germany) and Jacqueline Feser (University Hospital Zürich, Zürich, Switzerland).

**Supplementary data**

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhep.2019.10.010>.

**References**

- [1] The Polaris Observatory. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *Lancet Gastro Hepatol* 2017;2(3):161–166.
- [2] McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. *Hepatitis Interventional Therapy Group*. *N Engl J Med* 1998;339:1485–1492.
- [3] Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001;358:958–965.
- [4] Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med* 2011;364:2405–2416.
- [5] Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med* 2011;364:1195–1206.
- [6] Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). *J Viral Hepatitis* 2014;21:1–4.
- [7] Asselah T, Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. *Liver Int* 2011;31:68–77.
- [8] WHO. *Global Hepatitis Report 2017*. Geneva, 2017.
- [9] Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. *N Engl J Med* 2018;378:354–369.
- [10] Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. *J Hepatol* 2017;67:263–271.
- [11] Lamoury FM, Jacka B, Bartlett S, Bull RA, Wong A, Amin J, et al. The influence of hepatitis C virus genetic region on phylogenetic clustering analysis. *PLoS One* 2015;10:e0131437.
- [12] Lindstrom I, Kjellin M, Palanisamy N, Bondeson K, Wesslen L, Lannergard A, et al. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naïve patients with hepatitis C virus genotypes 1a and 3a in Sweden. *Infect Dis (Lond)* 2015;47:555–562.
- [13] Woods CK, Brumme CJ, Liu TF, Chui CKS, Chu AL, Wynhoven B, et al. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. *J Clin Microbiol* 2012;50:1936–1942.
- [14] Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. *J Hepatol* 2008;48:835–847.
- [15] Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003;38:518–526.
- [16] Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. *Clin Gastroenterol Hepatol* 2018;16:417–426.
- [17] ICH Expert Working Group. ICH harmonised tripartite guideline: Statistical principles for clinical trials E9, 1998.
- [18] Food and Drug Administration. *Non-Inferiority Clinical Trials to Establish Effectiveness: Guidance for Industry*. U.S. Department of Health and Human Services 2016.
- [19] Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. *Lancet Gastroenterol Hepatol* 2018.
- [20] Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med* 2005;353:487–497.
- [21] Petersen T, Townsend K, Gordon LA, Sidharthan S, Silk R, Nelson A, et al. High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. *Hepatol Int* 2016;10:310–319.
- [22] Mbuagbaw L, Sivaramalingam B, Navarro T, Hobson N, Keepanasseril A, Wilczynski NJ, et al. Interventions for enhancing adherence to antiretroviral therapy (ART): a systematic review of high quality studies. *Aids Patient Care Std* 2015;29:248–266.
- [23] Cooper V, Horne R, Gellaitry G, Vrijens B, Lange AC, Fisher M, et al. The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to Efavirenz-based HAART over 48 weeks: the NOCTE study. *J Acq Imm Def* 2010;53:369–377.
- [24] Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ, et al. Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. *HIV Med* 2008;9:667–672.
- [25] Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. *Clin Infect Dis* 2009;48:484–488.
- [26] Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. *EASL recommendations on treatment of hepatitis C 2018*. *J Hepatol* 2018;69:461–511.
- [27] AASLD-IDS. *Recommendations for testing, managing, and treating hepatitis C*. <http://www.hcvguidelines.org> (accessed 22-03-2019).